Literature DB >> 20433828

A 4-deoxy analogue of N-acetyl-D-glucosamine inhibits heparan sulphate expression and growth factor binding in vitro.

Xander M R van Wijk1, Arie Oosterhof, Sebastiaan A M W van den Broek, Arjan W Griffioen, Gerdy B ten Dam, Floris P J T Rutjes, Floris L van Delft, Toin H van Kuppevelt.   

Abstract

Heparan sulphate (HS) is a long, linear polysaccharide, which has a basic backbone of -beta1-4GlcA-alpha1-4GlcNAc- units. The involvement of HS in many steps of tumourigenesis, including growth and angiogenesis, makes it an appealing target for cancer therapy. To target the biosynthesis of HS by interfering with its chain elongation, a 4-deoxy analogue of N-acetyl-D-glucosamine (4-deoxy-GlcNAc) was synthesized. Using immunocytochemistry and agarose gel electrophoresis it was shown that incubation with the 4-deoxysugar resulted in a dose dependent reduction of HS expression of MV3 melanoma cells, 1 mM resulting in an almost nullified HS expression. The parent sugar GlcNAc had no effect. 4-deoxysugar treated cells were viable and proliferated at the same rate as control cells. Other glycan structures appeared to be only mildly affected, as staining by various lectins was generally not or only modestly inhibited. At 1 mM of the 4-deoxysugar, the capacity of cells to bind the HS-dependent pro-angiogenic growth factors FGF-2 and VEGF was greatly compromised. Using an in vitro angiogenesis assay, 4-deoxysugar treated endothelial cells showed a sharp reduction of FGF-2-induced sprout formation. Combined, these data indicate that an inexpensive, easily synthesized, water-soluble monosaccharide analogue can interfere with HS expression and pro-angiogenic growth factor binding. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20433828     DOI: 10.1016/j.yexcr.2010.04.025

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  6 in total

1.  A common sugar-nucleotide-mediated mechanism of inhibition of (glycosamino)glycan biosynthesis, as evidenced by 6F-GalNAc (Ac3).

Authors:  Xander M van Wijk; Roger Lawrence; Victor L Thijssen; Sebastiaan A van den Broek; Ran Troost; Monique van Scherpenzeel; Natasha Naidu; Arie Oosterhof; Arjan W Griffioen; Dirk J Lefeber; Floris L van Delft; Toin H van Kuppevelt
Journal:  FASEB J       Date:  2015-04-13       Impact factor: 5.191

2.  The polybasic insertion in autotaxin α confers specific binding to heparin and cell surface heparan sulfate proteoglycans.

Authors:  Anna J S Houben; Xander M R van Wijk; Laurens A van Meeteren; Leonie van Zeijl; Els M A van de Westerlo; Jens Hausmann; Alexander Fish; Anastassis Perrakis; Toin H van Kuppevelt; Wouter H Moolenaar
Journal:  J Biol Chem       Date:  2012-11-13       Impact factor: 5.157

3.  Small Molecule Antagonist of Cell Surface Glycosaminoglycans Restricts Mouse Embryonic Stem Cells in a Pluripotent State.

Authors:  Mia L Huang; Austen L Michalak; Christopher J Fisher; Mitchell Christy; Raymond A A Smith; Kamil Godula
Journal:  Stem Cells       Date:  2017-10-27       Impact factor: 6.277

4.  Interfering with UDP-GlcNAc metabolism and heparan sulfate expression using a sugar analogue reduces angiogenesis.

Authors:  Victor L Thijssen; Roger Lawrence; Xander M van Wijk; Sebastiaan A van den Broek; Margo Dona; Natasha Naidu; Arie Oosterhof; Els M van de Westerlo; Lisanne J Kusters; Yasmine Khaled; Tiina A Jokela; Patrycja Nowak-Sliwinska; Hannie Kremer; Sally E Stringer; Arjan W Griffioen; Erwin van Wijk; Floris L van Delft; Toin H van Kuppevelt
Journal:  ACS Chem Biol       Date:  2013-09-03       Impact factor: 5.100

5.  RNA Contaminates Glycosaminoglycans Extracted from Cells and Tissues.

Authors:  Jasper J van Gemst; Markus A Loeven; Mark J J de Graaf; Jo H M Berden; Ton J Rabelink; Cornelis H Smit; Johan van der Vlag
Journal:  PLoS One       Date:  2016-11-29       Impact factor: 3.240

6.  Selective Inhibition of Heparan Sulphate and Not Chondroitin Sulphate Biosynthesis by a Small, Soluble Competitive Inhibitor.

Authors:  Marissa L Maciej-Hulme; Eamon Dubaissi; Chun Shao; Joseph Zaia; Enrique Amaya; Sabine L Flitsch; Catherine L R Merry
Journal:  Int J Mol Sci       Date:  2021-06-29       Impact factor: 6.208

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.